The group treated with lecanemab 10 mg/kg monthly and 10 mg/kg biweekly, showed a substantial normalization of core AD and closely related biomarkers, with the increase in CSF Aβ1-42, reduction in CSF p-tau levels, and a trend regarding the reduction of CSF Ng and NfL [146]. This evidence concerns the gene MAPT and Alzheimer disease.